EP2797606A2 - Zusammensetzung und verwendung einer formulierung zur erhöhung des verhältnisses von gastrointestinalen mikrobioten in pflanzenstamm-bakterioditen für mikrobioten des firmuctes-pflanzenstamms - Google Patents

Zusammensetzung und verwendung einer formulierung zur erhöhung des verhältnisses von gastrointestinalen mikrobioten in pflanzenstamm-bakterioditen für mikrobioten des firmuctes-pflanzenstamms

Info

Publication number
EP2797606A2
EP2797606A2 EP12827673.0A EP12827673A EP2797606A2 EP 2797606 A2 EP2797606 A2 EP 2797606A2 EP 12827673 A EP12827673 A EP 12827673A EP 2797606 A2 EP2797606 A2 EP 2797606A2
Authority
EP
European Patent Office
Prior art keywords
formulation
body weight
glucan
dose
microbiota
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Withdrawn
Application number
EP12827673.0A
Other languages
English (en)
French (fr)
Other versions
EP2797606A4 (de
Inventor
Mark L. Heiman
Dean P. Stull
Justin W. PENO
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Microbiome Therapeutics LLC
Original Assignee
Microbiome Therapeutics LLC
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=47757119&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=EP2797606(A2) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Microbiome Therapeutics LLC filed Critical Microbiome Therapeutics LLC
Publication of EP2797606A2 publication Critical patent/EP2797606A2/de
Publication of EP2797606A4 publication Critical patent/EP2797606A4/de
Withdrawn legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/715—Polysaccharides, i.e. having more than five saccharide radicals attached to each other by glycosidic linkages; Derivatives thereof, e.g. ethers, esters
    • A61K31/733—Fructosans, e.g. inulin
    • A—HUMAN NECESSITIES
    • A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
    • A23L—FOODS, FOODSTUFFS, OR NON-ALCOHOLIC BEVERAGES, NOT COVERED BY SUBCLASSES A21D OR A23B-A23J; THEIR PREPARATION OR TREATMENT, e.g. COOKING, MODIFICATION OF NUTRITIVE QUALITIES, PHYSICAL TREATMENT; PRESERVATION OF FOODS OR FOODSTUFFS, IN GENERAL
    • A23L29/00—Foods or foodstuffs containing additives; Preparation or treatment thereof
    • A23L29/20—Foods or foodstuffs containing additives; Preparation or treatment thereof containing gelling or thickening agents
    • A23L29/206—Foods or foodstuffs containing additives; Preparation or treatment thereof containing gelling or thickening agents of vegetable origin
    • A23L29/212—Starch; Modified starch; Starch derivatives, e.g. esters or ethers
    • A—HUMAN NECESSITIES
    • A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
    • A23L—FOODS, FOODSTUFFS, OR NON-ALCOHOLIC BEVERAGES, NOT COVERED BY SUBCLASSES A21D OR A23B-A23J; THEIR PREPARATION OR TREATMENT, e.g. COOKING, MODIFICATION OF NUTRITIVE QUALITIES, PHYSICAL TREATMENT; PRESERVATION OF FOODS OR FOODSTUFFS, IN GENERAL
    • A23L33/00—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof
    • A—HUMAN NECESSITIES
    • A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
    • A23L—FOODS, FOODSTUFFS, OR NON-ALCOHOLIC BEVERAGES, NOT COVERED BY SUBCLASSES A21D OR A23B-A23J; THEIR PREPARATION OR TREATMENT, e.g. COOKING, MODIFICATION OF NUTRITIVE QUALITIES, PHYSICAL TREATMENT; PRESERVATION OF FOODS OR FOODSTUFFS, IN GENERAL
    • A23L33/00—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof
    • A23L33/10—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof using additives
    • A23L33/105—Plant extracts, their artificial duplicates or their derivatives
    • A—HUMAN NECESSITIES
    • A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
    • A23L—FOODS, FOODSTUFFS, OR NON-ALCOHOLIC BEVERAGES, NOT COVERED BY SUBCLASSES A21D OR A23B-A23J; THEIR PREPARATION OR TREATMENT, e.g. COOKING, MODIFICATION OF NUTRITIVE QUALITIES, PHYSICAL TREATMENT; PRESERVATION OF FOODS OR FOODSTUFFS, IN GENERAL
    • A23L33/00—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof
    • A23L33/20—Reducing nutritive value; Dietetic products with reduced nutritive value
    • A23L33/21—Addition of substantially indigestible substances, e.g. dietary fibres
    • A—HUMAN NECESSITIES
    • A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
    • A23L—FOODS, FOODSTUFFS, OR NON-ALCOHOLIC BEVERAGES, NOT COVERED BY SUBCLASSES A21D OR A23B-A23J; THEIR PREPARATION OR TREATMENT, e.g. COOKING, MODIFICATION OF NUTRITIVE QUALITIES, PHYSICAL TREATMENT; PRESERVATION OF FOODS OR FOODSTUFFS, IN GENERAL
    • A23L33/00—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof
    • A23L33/30—Dietetic or nutritional methods, e.g. for losing weight
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/045—Hydroxy compounds, e.g. alcohols; Salts thereof, e.g. alcoholates
    • A61K31/047—Hydroxy compounds, e.g. alcohols; Salts thereof, e.g. alcoholates having two or more hydroxy groups, e.g. sorbitol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/045—Hydroxy compounds, e.g. alcohols; Salts thereof, e.g. alcoholates
    • A61K31/05—Phenols
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/13—Amines
    • A61K31/155—Amidines (), e.g. guanidine (H2N—C(=NH)—NH2), isourea (N=C(OH)—NH2), isothiourea (—N=C(SH)—NH2)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/715—Polysaccharides, i.e. having more than five saccharide radicals attached to each other by glycosidic linkages; Derivatives thereof, e.g. ethers, esters
    • A61K31/716—Glucans
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/715—Polysaccharides, i.e. having more than five saccharide radicals attached to each other by glycosidic linkages; Derivatives thereof, e.g. ethers, esters
    • A61K31/716—Glucans
    • A61K31/718—Starch or degraded starch, e.g. amylose, amylopectin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
    • A61K36/18—Magnoliophyta (angiosperms)
    • A61K36/185—Magnoliopsida (dicotyledons)
    • A61K36/45—Ericaceae or Vacciniaceae (Heath or Blueberry family), e.g. blueberry, cranberry or bilberry
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
    • A61K36/18—Magnoliophyta (angiosperms)
    • A61K36/88—Liliopsida (monocotyledons)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
    • A61K36/18—Magnoliophyta (angiosperms)
    • A61K36/88—Liliopsida (monocotyledons)
    • A61K36/899—Poaceae or Gramineae (Grass family), e.g. bamboo, corn or sugar cane
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/22—Hormones
    • A61K38/28—Insulins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0087—Galenical forms not covered by A61K9/02 - A61K9/7023
    • A61K9/0095—Drinks; Beverages; Syrups; Compositions for reconstitution thereof, e.g. powders or tablets to be dispersed in a glass of water; Veterinary drenches
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/12—Antidiarrhoeals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
    • A23V—INDEXING SCHEME RELATING TO FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES AND LACTIC OR PROPIONIC ACID BACTERIA USED IN FOODSTUFFS OR FOOD PREPARATION
    • A23V2002/00—Food compositions, function of food ingredients or processes for food or foodstuffs
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0031—Rectum, anus
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/10—Dispersions; Emulsions

Definitions

  • the present invention relates to weight control and metabolic fitness. More particularly, the present invention relates to compositions and methods for increasing desirable microbiota in the human gut and reducing therein undesirable microbiota to achieve a healthy glucose regulation, metabolic fitness, inclusive intestinal health, and a healthy body weight.
  • HMP Human Microbiome Project
  • IHMC International Human Microbiome Consortium
  • the first GI microbiomes to be partially characterized are those obtained in the feces of obese and lean individuals (1,2).
  • Microbiota of the Firmicutes phylum are in abundance in the feces of obese individuals when compared to that of lean volunteers.
  • Microbiota of the other major division, Bacteroidetes are more abundant than those of Firmicutes division in lean individuals.
  • B:F ratio Firmuctes species to Bacteroidetes species
  • mice can be inoculated with microbiomes obtained from human feces of either obese or lean individuals. When fed a standard mouse chow, they either become obese or remain lean depending on the source of their GI microbiota transplant (4). Mice transplanted with human GI microbiota will become obese when fed a chow rich in simple sugars and fat after several weeks. The B:F ratio of those mice is increased when the diet is switched to one low in both fat and sugar but rich in plant polysaccharides (5,6).
  • Microbiota belonging to the Bacteriodetes phylum are specialists at transporting and metabolizing carbohydrates (7). They appear to forage on any available carbohydrate in their environment. Most sugars and starches, however, are metabolized by the host and are absorbed by the upper GI. Indigestible (by the host) carbohydrates do make it to the lower GI where they are consumed by members of the Bacteriodetes. The end products of this process are small chain fatty acids (SCFAs) that have health benefits for the host. Many of these indigestible carbohydrates are plant polysaccharides or more commonly called fiber or resistant starch and are classified as prebiotics (8). Microbiomes characterized in the feces of children maintained on a high fiber diet have a greater B:F ratio than those analyzed from feces of children consuming a typical European diet (9).
  • WO/2012/024638A2 COMPOSITIONS AND METHODS FOR TREATING OBESrfY AND RELATED DISORDERS BY CHARACTERIZING AND RESTORING MAMMALIAN BACTERIAL MICROBIOTA
  • EP2102350A2 THE GUT MICROBIOME AS A BIOMARKER AND THERAPEUTIC TARGET FOR TREATING OBESrfY OR AN OBESLTY RELATED DISORDER
  • Ghrelin is a growth-hormone-releasing acylated peptide from stomach. Nature 402: 656-60.
  • Unacylated ghrelin acts as a potent insulin secretagogue in glucose-stimulated conditions Am J Physiol Endocrinol Metab 293: E697-E704, 2007.
  • the present invention includes a composition and use of a formulation to increase the ratio of gastrointestinal microbiota in phylum Bacteroidetes to microbiota of Firmicutes phylum.
  • Figurel shows fasting blood glucose levels for 60 days of treatment; and Figure 2 shows fasting blood glucose levels for 60 days of treatment divided into 10 day periods.
  • One aspect of the present invention is to include an indigestible carbohydrate such as inulin, oligofructoses, fructo-oligosaccharides, lactulose,
  • an indigestible carbohydrate such as inulin, oligofructoses, fructo-oligosaccharides, lactulose,
  • GLP-1 stimulates the glucose sensing ability of the insulin secreting cell, prevents that cell from apoptosis, stimulates proliferation of those pancreatic beta cells and inhibits gastric emptying. GLP-1 also stimulates satiety but this may be due to its important role in decreasing gastric emptying.
  • Ghrelin is a hormone secreted by the stomach that stimulates appetite. Ghrelin is unique because it must be acylated with a medium chain fatty acid (MCFA) on the 3rd residue to bind and trigger its receptor (GHS-Rla) (10). Ghrelin comprised with octanoic (C-8)- or decanoic (C-10)- MCFAs are the most common forms of active ghrelin (10). There are also circulating carboxylesterases that cleave the acyl bond linking the fatty acid to the ghrelin backbone and render ghrelin inactive (11) with respect to appetite and nutrient consumption but may be beneficial for the treatment of T2DM (12).
  • GOAT ghrelin O- acyltransferase
  • Another novel aspect of the present invention is a formula designed to significantly enhance production of SCFAs by microbiota to serve as substrates for GOAT, render an inactive ghrelin and consequently decrease appetite.
  • the colon mucus layer is comprised of mucins, which are glycoproteins that have O-linked oligosaccharides or O-glycans, which account for up to 80% of the mass of mucin (17).
  • mucins are glycoproteins that have O-linked oligosaccharides or O-glycans, which account for up to 80% of the mass of mucin (17).
  • This mucus layer covers the gastrointestinal epithelium where it provides a protective layer from the rich intestinal microbiome as well as any pathogens.
  • Such endogenous source of glycans in the microbiome habitat could offer alternative nutrients.
  • dietary glycans it appears that harvesting energy from the diet is preferred (7).
  • an important aspect of the present invention includes dietary glycans. Most are indigestible carbohydrates. Since glycans are also in abundance in yeast walls, one source of dietary glycans is from yeast. Other sources include dietary beta- glucan. Beta-glucan is a natural polysaccharide that can be isolated from oat, barley and wheat most commonly, but also from baker's yeast, certain fungi, mushrooms, and bacteria. Addition of beta-glucan is an important component of the present invention to maintain the mucosa protective barrier as well as to offer nutrients to microbiota that prefer to forage on carbohydrates and would increase the B:F ratio.
  • Bacteroidetes and Firmicutes phyla is to suppress the growth of members of one division. Such bacteriostatic or bactericidal actions for members of Firmicutes division are reported for a number of phenolic compounds that are present in large quantities in berries and other fruits (18). Anthocyanins are the predominating group of phenolic compounds present in berries and are especially abundant (18). A large proportion of dietary polyphenolics remain unabsorbed in the gut lumen where they become concentrated in the ileum and colon. Up to 85% of blueberry anthocyanins enter the colon (19) and appear to exert more growth suppressing effects on members of the Firmicutes division than the Bacteroidetes division (20, 21). Although blueberry powder, blueberry pomace, or blueberry extract containing such polyphenolics is preferred, the present invention preferably includes any fruit or berry ingredient preparation containing similar phenolics such as those listed in Reference 18.
  • the three preferred classes of ingredients can be prepared in any type of edible product such as powder to mix in liquid, a bar, smoothie, yogurt, shake, etc.
  • the blend may also be prepared in a capsule or compressed into a tablet.
  • the formulation is to be ingested twice per day in between the first and second meals as well as between the second and third meals.
  • each dose of the formulation contain at least about 4g of indigestible polysaccharide, at least about 2g beta-glucan and at least about 4g of berry powder extract (the equivalent of 2 cups (16 ounces) or 0.47 liters whole blueberries containing about 800 mg of total phenolics, 100 mg of anthocyanins and 6900 ⁇ TE antioxidant activity). It is preferred that the dose be administered twice per day within 1 hour prior to meal 1 or within 1 hour prior to meal 2, as well as within 1 hour prior to meal 3. These are our best estimates but the formulation may change.
  • Ranges of ingredients preferably include about 2-120mg/kg of body weight of indigestible polysaccharide, about 2-80mg/kg of body weight of beta-glucan and about 2-120mg/kg of body weight of blueberry powdered extract or any fruit or berry ingredient preparation containing similar phenolics such as those listed in Reference 18. Ranges of these ingredients more preferably include about 10-80mg/kg of body weight of indigestible polysaccharide, about 5-50mg/kg of body weight of beta-glucan and about 10-80mg/kg of body weight of blueberry powder or any fruit or berry ingredient preparation containing similar phenolics such as those listed in Reference 18.
  • Ranges of these ingredients most preferably include about 20-60mg/kg of body weight of indigestible polysaccharide that is a fermentable fiber or resistant starch, about 10-30mg/kg of body weight of beta-glucan and about 20-60-320mg/kg of body weight of blueberry powdered extract or any fruit or berry ingredient preparation containing similar phenolics such as those listed in Reference 18.
  • One of these ingredients in a formulation is preferable to none, any two are preferable to only one, and most preferably all three are present in a formulation of the present invention that contains less than 70 usable Calories (Cal or kcal) (293 Kilojoules).
  • the calorie or joule content of the formulation can be calculated from derived constants determined for macronutrients in the formula.
  • a usable calorie or joule is only the calorie or joule that is assimilated or utilized for energy in the human body.
  • a preferred indigestible carbohydrate is inulin and can be found naturally in banana, asparagus, garlic, onions and wheat flour at low levels. To consume a sufficient quantity to achieve levels in the most preferred dose is possible but that would contribute significant usable calories or joules to the daily caloric intake of individuals who already have an unhealthy weight (see Table below) because the foods also contains usable calories or joules. Inulin content of raw Jerusalem artichoke, chicory root, and agave is high. Ingestion of a purified preparation of inulin contributes significantly less usable calories or joules to daily caloric intake than does ingestion of a vegetable containing inulin (see Table 1). To obtain the desired dose of inulin by eating the more common vegetable would contribute about 40 - times the calories or joules that purified inulin contributes.
  • Beta-glucan can be found naturally in oats, barley, mushrooms and Baker's yeast. To consume a sufficient quantity of these foods to achieve levels in the most preferred dose is possible but that would contribute significant useable calories or joules to the daily caloric intake of individuals who already have an unhealthy weight (see Table 2) because the foods also contains usable calories or joules.
  • Polyphenolics can be divided into major groups of anthocyanidins and flavonoids. They are found naturally in blueberry, cranberry, raspberry, and strawberry. These berries contain different levels of anthocyanidins and flavonoids according to Reference 22 and the abbreviated table below. Blueberries contain the broadest spectrum of polyphenolic compounds. Further, ingestion of the equivalent of 2 cups (16 ounces or 0.47 liters) of fresh blueberries provides sufficient bioactive compounds to improve insulin sensitivity in insulin resistant patients as demonstrated in Reference 23.
  • Pomace is the solid remains of blueberry after pressing for juice and thus removes sugar and water when manufacturing berry juice.
  • Pomace contains indigestible carbohydrate that accounts for 85% of calories or joules Pomace can be extracted with solvents such as alcohol or water to remove other useable calories.
  • Blueberry extracts of pomace contain less than 10 useable Calories (42 Kilojoules).
  • dosing may be once a day to initiate treatment and to acclimate the GI microbiome for up to 1 week and then switched to twice daily dosing. In other cases twice daily administration of half the optimal dose is desired such as in children or the elderly. In some cases optimal twice daily dosing may be changed to a daily dosing regimen to maintain the changes stimulated by twice daily dosing. In other cases the twice daily dosing may be switched to twice daily dosing of half the most preferred dose such as in children or adults who cannot tolerate preferred dosing.
  • the present invention can be used in combination with drugs.
  • broad spectrum antibiotics prescribed for systemic infections are not completely absorbed by the upper GI system and make it to the microbiota environment. This will temporarily alter the GI microbiome and it may be desirable to ingest the formulation of the present invention during antibiotic therapy, in preparation for a course of antibiotics, or following such intervention.
  • Specific antibiotics may target Gram positive or Gram negative bacteria. Treatment with a Gram positive antibiotic before-, during-, or following ingestion of the above combination of prebiotics of the present invention could improve the desired outcome.
  • a DPP-IV (dipeptidy peptidase type r ) inhibitor such as
  • the present invention can also be combined with other diabetes interventions such as biguanides.
  • An example includes metformin (Glucophage, Glucophage XR, Riomet, Fortamet, and Glumetza).
  • metformin Glucophage, Glucophage XR, Riomet, Fortamet, and Glumetza
  • metformin may not only improve blood glucose regulation but will counter the diarrhea side effect often associated with metformin (see Example 5). This is a potentially important clinical observation.
  • Metformin is recommended as the initial drug of choice for the treatment of type-2 diabetes (26).
  • Metformin has been reported to cause a 20% incidence of diarrhea in diabetic patients taking the drug compared to only 6% of diabetic patients not taking metformin (27). In fact, diarrhea with metformin is a sufficient problem that some diabetic patients cannot tolerate the drug. Since metformin has a good safety record, causes an approximate 2-3 kg weight loss and is a low-cost generic medication, increasing the tolerance to metformin while increasing its efficacy using a safe food supplement could have beneficial public health consequences.
  • the present invention may also be combined with alpha- glucosidase inhibitors such as Precose (acarbose) and Glyset (miglitol) that are effective in controlling blood glucose but are poorly tolerated because of associated diarrhea.
  • some drugs such as atypical antipsychotics and insulin cause weight gain in some patients. The present invention could be combined with such drugs to combat the weight gain without intervening with antipsychotic efficacy.
  • IBS Irritable bowel syndrome
  • IBS-C Irritable bowel syndrome
  • IBS-D Irritable bowel syndrome
  • the key symptom of IBS is abdominal pain or discomfort anywhere in the abdomen. It may change over time.
  • the impact of IBS can range from mild inconvenience to severe debilitation. Persons with moderate to severe IBS must struggle with symptoms that often impair their physical, emotional, economic, educational and social well-being. The exact cause of IBS is not known.
  • the present invention can be used in preparation for fecal transplant or fecal bacteriotherapy and its follow up.
  • Fecal microbiota transplantation is the process of transplantation of fecal microbiota from a healthy individual into a recipient as a treatment for diseases such as infection by Clostridium difficile (29) or more recently, type 2 diabetes (30).
  • Guidelines for both the donor and the recipient are being prepared and will likely indicate strategies for both the donor and the recipient.
  • the use of the present invention in preparation of both subjects for the procedure and continued use by the recipient after transplantation will increase the probability of a successful outcome.
  • the present invention can also be used in preparation for fecal banking. Such practice will permit a subject to prepare a specific fecal sample for banking until needed. This may occur in preparation of prolonged antibiotic surgery, cancer chemotherapy and an unforeseen chronic illness.
  • the present invention can be used to treat ocular diseases. Recently, it was demonstrated that the microbiota of a conventional raised laboratory mouse adversely alters the ocular lens (31). The present invention is designed to cause a shift in the GI microbiome. Thus, the invention will be useful in prevention of cataracts. Another eye syndrome is commonly called dry-eye syndrome (DES). Traditionally, DES has been thought of as a deficiency of tears at the ocular surface. In recent years, however, investigators have shown that DES is much more complex than previously thought, and that "tear film dysfunction syndrome" might more accurately describe the condition. Tear film dysfunction can be broken down into two basic etiologic classifications: insufficient tear production or increased evaporation of tears from the eye surface (32).
  • the tear film is made up of lipid, aqueous and mucin components. Individuals with dry eye syndrome can be deficient in any of these components and all appear to be related, in part, to healthy GI function. Thus, the present invention will be useful in treating DES.
  • TG is triglyceride
  • lactitol lactitol, sorbitol, maltitol
  • GLP-1 into the blood, systems, reduced produce inactive ghrelin. increase environment.
  • FORMULA A is made of 4.7g dried blueberry pomace extract powder from Milne Fruit Products (Prosser, WA, product no. FG20155), 9.22g OatWell 22 ® beta glucan from CreaNutrition (Sweden), 4.4g agave inulin (Inufib) from The Iidea Company (Tlaquepaque, Jal., Mexico), with inactive ingredients preferably added for flavor, mouth feel, texture and mixing, including 8.5g erythritol, 0.5g soy protein, 0.4g xanthan gum, 0.38g citric acid, 0.14g stevia, and 0.4g natural flavor that are not believed to affect the efficacy of Formula A.
  • FORMULA A is to be added to a liquid such as 180ml of water, milk, juice, etc., mixed and consumed as a suspension.
  • the dried blueberry pomace extract powder used in connection with the present invention is preferably blueberry extract powder, product no. FG20155, available from Milne Fruit Products of Prosser, Washington.
  • Formula A is used in the examples below.
  • One dose of FORMULA A provides 120% of the recommended daily dietary allowance (RDA) of antioxidant activity for children and adults as well as 30% dietary fiber for men and 50% dietary fiber for women, 60% dietary fiber for children aged 1-3, 45% dietary fiber for children aged 4-8, 36% dietary fiber for boys of ages 9-13, and 45% of dietary fiber for girls of ages 9-13.
  • RDA recommended daily dietary allowance
  • a dose of Formula A is taken at least once per day, more preferably at least twice per day, and even more preferably at least 3 times per day.
  • Each dose of FORMULA A is analyzed to contain active and inactive ingredients described in the table 8:
  • OGTT oral glucose tolerance test
  • Placebo formula contains cellulose with food coloring and flavor to match the total dietary fiber content (8.75g) of FORMULA A. Placebo is prepared by Merlin Development at the same time they prepare
  • a total of 30 subjects is selected, 15 assigned to FORMULA A and 15 assigned to placebo.
  • g) are hypothyroid,
  • SCREENING Subjects are screened to exclude hypothyroidism, pregnancy, and heart disease. The following tests can suffice for this: T4 (thyroxin), T3 (triiodotyronine), TSH (thyroid stimulating hormone), urine pregnancy test, blood pressure & ECG (electrocardiogram).
  • step 2 a) all labs and assessments done in step 2 at beginning of study, b) Analysis of the fecal microbiome DNA from both the initial sample and the final sample.
  • Subjects selected for participation are allowed an ad libitum diet and are given an evaluation sheet to assess their appetite and satiety before and after a meal.
  • Foods excluded include alcohol.
  • Low calorie or joule liquids are stressed in place of high calorie or joule liquids such as fruit juices, milk, sweet tea (tea with sugar), regular soft drinks, coffee with sugar, etc.
  • the subjects are randomly assigned to either FORMULA A or placebo treatments. Both the experimenter and the subjects are blinded to who receive FORMULA A or the placebo. The subjects are encouraged to consume either treatment within 1 hour prior to either breakfast or lunch and within 1 hour prior to dinner.
  • Subjects are given a 4 weeks supply of either FORMULA A or placebo at the onset and are instructed to consume the entire 180ml volume within 1 hour prior to either meals 1 or 2, as well as another 180ml volume containing either FORMULA A or placebo within 1 hour prior to meal 3.
  • Ad libitum diets are followed for 4 weeks, but the volunteers are instructed to consume either FORMULA A or placebo as their only between meal snack.
  • Placebo formula contains cellulose with food coloring and flavor to match the total dietary fiber content (8.75g) of FORMULA A.
  • Placebo is prepared by Merlin Development at the same time they prepare FORMULA A. Both formulations are coded by Merlin Development and the code is maintained with them as well as is held in confidence by a pharmacist at the study clinic until all data are collected at the end of study.
  • a total of 30 subjects is selected. Fifteen subjects are randomly assigned to consume FORMULA A and the remaining 15 subjects are assigned to the FORMULA A group. The demographics of each group are carefully matched.
  • g) are hypothyroid, h) are pregnant,
  • SCREENING Subjects are screened to exclude hypothyroidism, pregnancy, and heart disease. The following tests can suffice for this: T4 (thyroxin), T3 (triiodotyronine), TSH (thyroid stimulating hormone), urine pregnancy test, blood pressure & ECG (electrocardiogram).
  • Subjects selected for participation are allowed an ad libitum diet and are given an evaluation sheet to assess their appetite and satiety before and after a meal.
  • Foods excluded include alcohol.
  • Low calorie or joule liquids are stressed in place of high calorie or joule liquids such as fruit juices, milk, sweet tea (tea with sugar), regular soft drinks, coffee with sugar, etc.
  • the subjects are encouraged to consume either FORMULA A or Placebo as their only between meal snack.
  • Subjects are given a 4 weeks supply of ether FORMULA A or Placebo at the onset and are instructed to consume the entire 180ml volume containing either formula within 2 hours prior to either meals 1 or 2, as well as another 180ml volume containing either formula within 2 hours prior to meal 3.
  • Ad libitum diets are followed for 4 weeks, but the volunteers are instructed to consume either FORMULA A or Placebo as their only between meal snack.
  • Dipeptidyl peptidase-4 (DPP-4) to Increase the Ratio of Gastrointestinal Microbiota in Phylum Bacteroidetes to Microbiota of Firmicutes Phylum and Improve Glucose Regulation by Sustained Elevation of GLP-1
  • T2D Type 2 diabetic subjects with insulin resistance on an ad libitum diet who take a DPP-4 inhibitor and FORMULA A within 1 hour prior to either meal 1 or meal 2, as well as within 1 hour prior to meal 3 for 4 weeks:
  • Insulin sensitivity is measured by an oral glucose tolerance test (OGTT). This is performed by measuring blood glucose and insulin levels before, during, and at 120 minutes after ingestion of 75g glucose when compared to their initial OGTT, and
  • T2D patients are randomly assigned to either consume 180ml of FORMULA A or a placebo formula containing cellulose orally within 1 hour prior to either meals 1 or 2 as well as within 1 hour prior to meal 3 each day. Patients and experimenters are blinded to this assignment. All patients are also instructed to take sitagliptin (Januvia®) at the recommended dose of lOOmg, once per day in the morning prior to meal 1 as a treatment to manage their diabetes.
  • Januvia® + placebo a cellulose solution that contains the same total dietary fiber content as FORMULA A and mimics FORMULA A in color and taste
  • g) are hypothyroid,
  • SCREENING Subjects are screened to exclude hypothyroidism, pregnancy, and heart disease. The following tests can suffice for this: T4, T3, TSH, urine pregnancy test, blood pressure & ECG. Fasting blood glucose, fasting insulin and HgbAl levels are also measured as an assessment of their diabetic state.
  • STUDY DESIGN Patients selected for participation are allowed an ad libitum diet and are given an evaluation sheet to assess their appetite and satiety. Foods excluded include alcohol. Low calorie or joule liquids are stressed in place of high calorie or joule liquids such as fruit juices, milk, sweet tea (tea with sugar), regular soft drinks, coffee with sugar, etc. All 24 patients are also instructed to take sitagliptin (Januvia®) at the recommended dose of lOOmg, once per day in the morning with or without food as a treatment to manage their diabetes. 12 patients are randomly selected to also consume FORMULA A before 2 of 3 daily meals and the remaining 12 patients are instructed to consume a placebo before 2 of 3 daily meals. Patients and investigators are blinded to whether the snack replacement is placebo or FORMULA A.
  • Subjects are given a 4 weeks supply of sitagliptin and either FORMULA A or placebo at the onset and are instructed to consume the entire 180ml volume of either snack replacement within 1 hour prior to either meals 1 or 2, as well as another 180ml volume of snack replacement within 1 hour prior to meal 3. All subjects are required to take 1 tablet of sitagliptin daily (lOOmg) in the morning with or without food. Ad libitum diets are followed for 4 weeks. OUTCOME
  • OGTT oral glucose tolerance test
  • g) are hypothyroid,
  • SCREENING Children are screened to exclude hypothyroidism and puberty. The following tests can suffice for this: T4, T3, TSH, a physical exam, and in questionable cases based on the physical exam or peripubertal presentations, a gonadotropin- releasing hormone challenge test.
  • step 2 a) all labs and assessments done in step 2 at beginning of study, b) Analysis of the fecal microbiome DNA from both the initial sample and the final sample.
  • JH was a 30 year old Caucasian male who gained 10 kg over the course of 8 months and developed lower back pain. He presented to his primary physician with that complaint.
  • omeprazole (20mg/d), lisinopril (40mg/d), metoprolol (lOOmg/d), and hydrochlorothiazide (25mg/d) at the time of his presentation, had no allergies and had undergone no surgeries. He denied past hospitalizations, trauma with residua or blood transfusions. He had never smoked, drank 3-4 alcoholic drinks per week on average and had no history of intravenous drug use. He was a full-time law student and had no exposures to occupational toxins. During the 6 months prior to his presentation he had been sexually active with one woman. The patient's mother and father were living and well.
  • BMI body mass index
  • Figurel shows fasting blood glucose levels at the start of lOOOmg metformin twice daily.
  • Formula A was added twice daily on day 9 and the combination was continued except from days 49 to 51 when daily dosing of FORMULA A was missed.
  • Diarrhea was associated with metformin except when Formula A was added.
  • Acarbose is another drug used to treat diabetes that is associated with the side effect of a watery stool because of its mechanisms of action. If FORMULA A is used in conjunction with acarbose to treat type 2 diabetes, both better control of blood glucose and solid stool formation are expected.
  • Placebo formula contains cellulose with food coloring and flavor to match the total dietary fiber content (8.75g) of FORMULA A.
  • Placebo is prepared by Merlin Development at the same time they prepare FORMULA A. Both formulations are coded by Merlin Development and the code is maintained with them as well as is held in confidence by a pharmacist at the study clinic until all data are collected at the end of study.
  • Pain and bowel function data are collected during the screening phase to ensure that patients had a suitable symptom level at study entry. Severity of pain and discomfort was assessed daily on a 5-point scale (0, none; 1, mild; 2, moderate; 3, intense; and 4, severe). Stool consistency data are monitored daily and scored as follows: 1, very hard; 2, hard; 3, formed; 4, loose; and 5, watery. Absence of stool was assigned a value of 0. Patients also record their IBS symptoms urgency (0%, feel no need to evacuate - 100%, feel severe need to evacuate), stool frequency (# of stools per day), bloating (0, no sensation of extended abdomen; 1, mild; 2, moderate; 3, severe) and sense of incomplete evacuation (0, sensation of complete evacuation; 1, incomplete; 2, constipated) daily during the treatment and follow-up phases.
  • Physicians are provided with a guideline based on the percentage of time the patient had experienced diarrhea. If diarrhea is present for >75% of the time, then the patient is classified as being diarrhea predominant.
  • Patients are excluded if they are pregnant, breastfeeding, or not using approved methods of contraception (if of child-bearing potential); if an unstable medical or other gastrointestinal condition exists; if there is a major psychiatric disorder or substance abuse within the previous 2 years; if an investigational drug was used within 30 days of the screening phase; or if a prohibited concurrent medication (likely to interfere with gastrointestinal tract function or analgesia) was used within 7 days before entering the screening phase.
  • Pain and bowel function data are collected during the screening phase to ensure that patients had a suitable symptom level at study entry as described above.
  • Evaluations are performed at the screening of potential participants, at the beginning of the study, daily, and at the end of the 4 week treatment period.
  • Severity of pain and discomfort is assessed on a 5-point scale (0, none; 1, mild; 2, moderate; 3, intense; and 4, severe).
  • Stool is collected and stored frozen but not analyzed until the end of study.
  • Subjects selected for participation are allowed an ad libitum diet. Foods excluded include alcohol. The subjects are encouraged to consume either FORMULA A or Placebo within 1 hour prior to 2 meals each day with ingestion of the test agent being mandatory prior to the 3 rd meal.
  • Subjects are given a 4 week supply of ether FORMULA A or Placebo at the onset and are instructed to consume the entire 180ml volume containing either formula within 1 hour prior to either meals 1 and 2, as well as another 180ml volume containing either formula within 1 hour prior to meal 3.
  • Subjects report weekly for measurements and assessment of IBS symptoms. During the screening and treatment periods, daily symptom data are collected using an interactive telephone-based system.
  • FORMULA A to treat idiopathic diarrhea such as a parasitic infection, a viral infection and a symptomatic response to a food is expected to also improve the severity of pain and discomfort, increase stool consistency, decrease the urgency to evacuate, decrease stool frequency, and decrease the sensation of bloating.
  • Example 7 Utilization of FORMULA A to treat idiopathic diarrhea such as a parasitic infection, a viral infection and a symptomatic response to a food is expected to also improve the severity of pain and discomfort, increase stool consistency, decrease the urgency to evacuate, decrease stool frequency, and decrease the sensation of bloating.
  • difficile infection initially presents to her primary care physician diarrhea of 8 months duration that originally started shortly following treatment with cephalosporin and quinolone antibiotics for back surgery and a pulmonary infection. During these eight months, she is repeatedly treated with metronidazole and vancomycin, and required several hospitalizations for intravenous hydration. The patient complains of loose small bowel movements every 15 minutes, accompanied by great urgency and rectal tenesmus. She wears diapers at all times and loses 10% of her body weight. Flexible sigmoidoscopy demonstrates classic pseudomembranous colitis. Stool samples are positive for C. difficile toxins A and B, and stool culture confirms heavy growth of this bacterium. The patient is again treated with vancomycin, but fails to respond.
  • nitazoxanide (2-acetyloxy-N-(5-nitro-2- thiazolyl)benzamide), 500 mg orally, twice daily.
  • nitazoxanide (2-acetyloxy-N-(5-nitro-2- thiazolyl)benzamide
  • fecal bacteriotherapy is offered to break the cycle of recurrences and achieve a potential cure.
  • Informed consent is obtained from both the patient and the donor following discussion with each of the potential risks, benefits, and alternative options.
  • the patient is maintained on Nitazoxanide until the day before the procedure.
  • the patient's husband of 44 years (donor) is prescribed FORMULA A 3 times a day for 2 weeks.
  • Fecal donor material is taken from him, who has no risk factors for blood-borne communicable diseases, has no recent exposure to antibiotics, has no gastrointestinal symptoms of any kind, and tests negative for common stool pathogens and C. difficile.
  • Bacteriotherapy is delivered into the patient's right colon by way of a colonoscopy.
  • the patient is expected to have her first solid bowel movement on the second day following treatment. It is expected that her abdominal pain gradually subsides, and at one month following bacteriotherapy and it is expected that her stool samples will be negative for C. difficile.
  • the patient is expected to commence FORMULA A twice a day. At six months follow-up, the patient is expected to report once-daily formed stools.

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Medicinal Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Epidemiology (AREA)
  • Natural Medicines & Medicinal Plants (AREA)
  • Mycology (AREA)
  • Nutrition Science (AREA)
  • Polymers & Plastics (AREA)
  • Food Science & Technology (AREA)
  • Botany (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Molecular Biology (AREA)
  • Diabetes (AREA)
  • Medical Informatics (AREA)
  • Microbiology (AREA)
  • Alternative & Traditional Medicine (AREA)
  • Biotechnology (AREA)
  • Organic Chemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Endocrinology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Zoology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Immunology (AREA)
  • Dispersion Chemistry (AREA)
  • Obesity (AREA)
  • Hematology (AREA)
  • Emergency Medicine (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Coloring Foods And Improving Nutritive Qualities (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
EP12827673.0A 2011-08-17 2012-08-17 Zusammensetzung und verwendung einer formulierung zur erhöhung des verhältnisses von gastrointestinalen mikrobioten in pflanzenstamm-bakterioditen für mikrobioten des firmuctes-pflanzenstamms Withdrawn EP2797606A4 (de)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201161524524P 2011-08-17 2011-08-17
PCT/US2012/051408 WO2013032744A2 (en) 2011-08-17 2012-08-17 Composition and use of a formulation to increase the ratio of gastrointestinal microbiota in phylum bacteriodites to microbiota of firmuctes phylum

Publications (2)

Publication Number Publication Date
EP2797606A2 true EP2797606A2 (de) 2014-11-05
EP2797606A4 EP2797606A4 (de) 2015-09-30

Family

ID=47757119

Family Applications (1)

Application Number Title Priority Date Filing Date
EP12827673.0A Withdrawn EP2797606A4 (de) 2011-08-17 2012-08-17 Zusammensetzung und verwendung einer formulierung zur erhöhung des verhältnisses von gastrointestinalen mikrobioten in pflanzenstamm-bakterioditen für mikrobioten des firmuctes-pflanzenstamms

Country Status (5)

Country Link
US (4) US9463169B2 (de)
EP (1) EP2797606A4 (de)
JP (3) JP5877902B2 (de)
CA (1) CA2878005C (de)
WO (1) WO2013032744A2 (de)

Families Citing this family (40)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2013032744A2 (en) 2011-08-17 2013-03-07 Nume Health, Llc Composition and use of a formulation to increase the ratio of gastrointestinal microbiota in phylum bacteriodites to microbiota of firmuctes phylum
BR112014021388A2 (pt) 2012-02-29 2017-07-18 Ethicon Endo Surgery Inc composições de microbiota e métodos rela-cionados às mesmas
US20150296851A1 (en) * 2012-11-27 2015-10-22 Shanghai Jiao Tong University Compositions for Balancing Gut Microbiota and the Preparation and the Uses thereof
WO2014091017A2 (en) * 2012-12-13 2014-06-19 Metabogen Ab Identification of a person having risk for developing type 2 diabetes
CN106663137B (zh) 2014-04-28 2020-07-10 耶达研究及发展有限公司 用于预测对食物的反应的方法和装置
WO2015200842A1 (en) * 2014-06-26 2015-12-30 MicroBiome Therapeutics LLC Composition comprising metformin and a microbiome modulator
EP3209803A4 (de) 2014-10-21 2018-06-13 Ubiome, Inc. Verfahren und zusammensetzungen für mikrobiom-diagnostika und -therapeutika
US10325685B2 (en) 2014-10-21 2019-06-18 uBiome, Inc. Method and system for characterizing diet-related conditions
EP3881680A1 (de) 2014-10-31 2021-09-22 Pendulum Therapeutics, Inc. Verfahren und zusammensetzungen im zusammenhang mit mikrobieller behandlung von störungen
WO2016139217A1 (en) * 2015-03-04 2016-09-09 Ab-Biotics, S.A. Composition comprising anaerobically cultivated human intestinal microbiota
DK3285777T3 (da) 2015-04-23 2021-08-30 Kaleido Biosciences Inc Glycan-terapier og fremgangsmåder til behandling
EP3915552A1 (de) * 2015-06-01 2021-12-01 Xeno Biosciences Inc. Zusammensetzungen zur verwendung bei der modulation der darm-mikrobiota und der gewichtskontrolle
WO2017075078A1 (en) 2015-10-26 2017-05-04 Brandeis University Fruit or vegetable pomace composition and use as blood glucose modulator and anti-diabetic agent
US20210137964A1 (en) * 2016-07-13 2021-05-13 Kaleido Biosciences, Inc. Glycan compositions and methods of use
US20180030403A1 (en) 2016-07-28 2018-02-01 Bobban Subhadra Devices, systems and methods for the production of humanized gut commensal microbiota
AU2017318650B2 (en) 2016-09-02 2021-12-09 Société des Produits Nestlé S.A. Compositions and methods for modulating gastrointestinal microflora in a canine
JP7011885B2 (ja) * 2016-10-27 2022-01-27 エヌエスイー プロダクツ、インク． 腸の健康を促す組成物
EP3768851A4 (de) * 2016-12-15 2022-03-09 Psomagen, Inc. Verfahren und system zur charakterisierung von diätbezogenen zuständen
WO2018171850A1 (en) * 2017-03-23 2018-09-27 Københavns Universitet Prebiotic compounds or compositions for use in treatment of sjögren's syndrome
CN111372596A (zh) 2017-08-30 2020-07-03 潘德勒姆治疗公司 用于治疗微生物组相关病症的方法和组合物
JP7150282B2 (ja) * 2017-09-14 2022-10-11 協同乳業株式会社 涙液分泌能・涙液安定性を改善するための飲食品または製剤
CA3088630A1 (en) 2017-12-15 2019-06-20 Solarea Bio, Inc. Microbial compositions and methods for treating type 2 diabetes, obesity, and metabolic syndrome
US11484547B2 (en) * 2018-01-08 2022-11-01 Performance Labs PTE. LTD. Compositions and methods for cholesterol, glucose and microbiome control
US20210008028A1 (en) * 2018-03-23 2021-01-14 Vanessa Research, Inc. Compositions and methods for treating diarrheal diseases
US11980647B2 (en) 2018-09-05 2024-05-14 Solarea Bio, Inc. Methods and compositions for treating musculoskeletal diseases, treating inflammation, and managing symptoms of menopause
CA3111795A1 (en) 2018-09-05 2020-03-12 Solarea Bio, Inc. Methods and compositions for treating musculoskeletal diseases
EP3685681B1 (de) * 2019-01-23 2024-07-31 Lesaffre et Compagnie Hefeprodukt, und zusammensetzung enthaltend dieses, zur verwendung als präbiotikum
JP7352275B2 (ja) * 2019-05-16 2023-09-28 国立大学法人弘前大学 更年期症状改善用組成物
US11311478B2 (en) 2020-06-26 2022-04-26 Uplift Food Prebiotic and probiotic cookie preparation
GB202003327D0 (en) * 2020-03-06 2020-04-22 Lucozade Ribena Suntory Ltd Beverage composition and method of forming the same
US11883176B2 (en) 2020-05-29 2024-01-30 The Research Foundation For The State University Of New York Low-power wearable smart ECG patch with on-board analytics
JP7279943B2 (ja) * 2020-07-03 2023-05-23 株式会社エーゼット ブドウ種子抽出物を含む更年期障害改善剤
EP4203712A1 (de) * 2020-08-31 2023-07-05 Société des Produits Nestlé S.A. Personalisierung von diätfaserzusammensetzungen, verfahren und systeme dafür
JP7220687B2 (ja) * 2020-09-14 2023-02-10 メロディアン株式会社 イヌリン含有液体食品及びその製造方法
IT202000024509A1 (it) * 2020-10-16 2022-04-16 Adriana Basile “composizione di nutraceutico con attività antitumorale”
US20220257692A1 (en) * 2021-02-17 2022-08-18 Plexus Worldwide, Llc Compositions and methods for supporting immune health
AU2022391767A1 (en) 2021-11-22 2024-07-04 Solarea Bio, Inc. Methods and compositions for treating musculoskeletal diseases, treating inflammation, and managing symptoms of menopause
US20230190834A1 (en) 2021-12-21 2023-06-22 Solarea Bio, Inc. Immunomodulatory compositions comprising microbial entities
WO2024026399A1 (en) * 2022-07-29 2024-02-01 Kimberly-Clark Worldwide, Inc. Methods and compositions related to prebiotic formulations useful in promoting urogenital health
KR20240114298A (ko) 2023-01-12 2024-07-23 에스엔제이 파마 인크 감염 저항성 장내 균주 및 그 용도

Family Cites Families (41)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4418710A (en) 1981-10-05 1983-12-06 Eaton Corporation Pilot control valve for load sensing hydraulic system
EP1094722A1 (de) 1999-04-27 2001-05-02 Diomeda Antonio Tortora Nutraceuticals und nahrungsbestandteile für wirksames nahrungsmittel
JP2001046030A (ja) 1999-08-02 2001-02-20 Tama Seikagaku Kk ブルーベリー抽出エキスの製造法
EP1242113A2 (de) 1999-12-30 2002-09-25 University Of Louisville Research Foundation, Inc. Methoden und zusammensetzungen zur hemmung der adhäsion von mikroorganismen
US6277434B1 (en) * 2000-05-30 2001-08-21 Sally E. Matluk-Boisseau Pet food product and methods of product manufacture and distribution
EP1214893A1 (de) * 2000-12-16 2002-06-19 Aventis Pharma Deutschland GmbH Zusammensetzungen zur Verbesserung der Gesundheit
PT1638418E (pt) 2003-06-23 2012-09-20 Nestec Sa Suplementação de aminoácidos para um ecossistema de flora microbiana saudável
EP1670934B1 (de) 2003-10-02 2008-10-29 Nestec S.A. Präbiotische effektanalyse
US20050239706A1 (en) 2003-10-31 2005-10-27 Washington University In St. Louis Modulation of fiaf and the gastrointestinal microbiota as a means to control energy storage in a subject
DE602004027120D1 (de) * 2004-05-25 2010-06-24 Cognis Ip Man Gmbh Orale und/oder topische Zubereitungen
GB0414655D0 (en) 2004-06-30 2004-08-04 Leuven K U Res & Dev Prebiotic
US20100048595A1 (en) 2005-03-23 2010-02-25 Washington University In St. Louis Use of archaea to modulate the nutrient harvesting functions of the gastrointestinal microbiota
HUP0500582A1 (hu) 2005-06-13 2007-08-28 Csaba Jozsef Dr Jaszberenyi Szinergetikus élettani hatású élelmiszerek, élelmiszer-adalékok és táplálék-kiegészítõk vagy takarmányadalékok
DK1965809T3 (da) 2005-11-21 2010-01-04 Bioatlantis Ltd Præparater til forbedring af sundhedstilstanden i dyrs tarmsystem og dyrs ydeevne omfattende Beta-glucanerne og Alfa-fucaner
US20090311370A1 (en) 2006-06-08 2009-12-17 Agave Inc. And Universidad Autonoma De Guadalajara Highly water-soluble agave inulin, agave inulin-containing product, agave inulin-origin product, by-product and method for producing the same
EP2102350A4 (de) 2006-12-18 2012-08-08 Univ St Louis Darmmikrobiom als biomarker und therapeutisches ziel zur behandlung von adipositas oder adipositasbedingten erkrankungen
EP1974743A1 (de) 2007-03-28 2008-10-01 Nestec S.A. Probiotika zur Verbesserung der Darm-Biozönose
EP1985712A1 (de) 2007-04-17 2008-10-29 Vereniging voor christelijk hoger onderwijs, wetenschappelijk onderzoek en patiëntenzorg Analyse einer mikrobiellen Population
EP2149047A4 (de) 2007-04-30 2010-05-19 Univ Ohio State Res Found Polymorphismen in genen mit einfluss auf dopamintransporter-erkrankungen und ihre anwendungen
JP2009026355A (ja) 2007-07-17 2009-02-05 Toshiba Corp 半導体記憶装置及びその制御方法
EP2030623A1 (de) 2007-08-17 2009-03-04 Nestec S.A. Verhinderung und/oder Behandlung von Stoffwechselerkrankungen durch Modulation der Menge der Enterobakterien
US9131721B2 (en) 2007-12-04 2015-09-15 Nestec S.A. Gut microbiota in infants
WO2009075564A1 (en) 2007-12-10 2009-06-18 N.V. Nutricia Paediatric fibre mixture
WO2009082214A1 (en) 2007-12-21 2009-07-02 N.V. Nutricia Use of non-digestible carbohydrates for improving intestinal microbiota
US7544466B1 (en) 2007-12-29 2009-06-09 Board Of Regents, The University Of Texas System Ghrelin o-acyltransferase (GOAT) biochemical assay
JP5528718B2 (ja) * 2008-03-31 2014-06-25 株式会社Ａｄｅｋａ βグルカン組成物を用いた血糖値上昇抑制剤及びインスリン分泌促進剤
WO2010002890A2 (en) 2008-06-30 2010-01-07 The Washington University Methods of promoting weight loss and associated arrays
US8268374B2 (en) * 2008-08-18 2012-09-18 Creative Resonance, Inc. Pet food and process of manufacture
US8013015B2 (en) 2008-10-02 2011-09-06 Board Of Regents, The University Of Texas System Small molecule inhibitors of ghrelin O-acyltransferase
WO2010102056A1 (en) 2009-03-03 2010-09-10 Solazyme, Inc. Methods of treating impaired glucose metabolism via administration of algal biomass
NZ595174A (en) 2009-03-13 2013-04-26 Univ California Prebiotic galacto oligosaccharides used to stimulate growth or colonisation of beneficial bifidobacterium bacteria in gut
US20120165215A1 (en) 2009-06-26 2012-06-28 The Regents Of The University Of California Methods and systems for phylogenetic analysis
EP2467145B2 (de) 2009-08-18 2020-02-05 Cosucra-groupe Warcoing Sa Zusammensetzungen mit gemischen aus fermentierbaren fasern
WO2011022660A1 (en) 2009-08-21 2011-02-24 Puretech Ventures, Llc Methods of diagnosing and treating microbiome-associated disease using interaction network parameters
ITMI20091553A1 (it) * 2009-09-10 2011-03-11 Mauro Vincenzo Bonelli Fascia di accoppiamento per contenitori quali bottiglie e similari, confezione multipla di contenitori quali bottiglie e similari nonchè procedimento di realizzazione della confezione stessa
WO2011060307A2 (en) * 2009-11-13 2011-05-19 Jingxuan Kang Food products having multiple health benefits
WO2011103123A2 (en) 2010-02-16 2011-08-25 Arizona Technology Enterprises Reducing short-chain fatty acids and energy uptake in obese humans by managing their intestinal microbial communities
CA2791464A1 (en) 2010-03-01 2011-09-09 Institut National De La Recherche Agronomique Method of diagnosis of obesity
US8951512B2 (en) 2010-05-04 2015-02-10 New York University Methods for treating bone disorders by characterizing and restoring mammalian bacterial microbiota
WO2012024638A2 (en) 2010-08-20 2012-02-23 New York University Compositions and methods for treating obesity and related disorders by characterizing and restoring mammalian bacterial microbiota
WO2013032744A2 (en) 2011-08-17 2013-03-07 Nume Health, Llc Composition and use of a formulation to increase the ratio of gastrointestinal microbiota in phylum bacteriodites to microbiota of firmuctes phylum

Also Published As

Publication number Publication date
US20190374570A1 (en) 2019-12-12
WO2013032744A2 (en) 2013-03-07
US20150118330A1 (en) 2015-04-30
CA2878005A1 (en) 2013-03-07
US20170080015A1 (en) 2017-03-23
US20140294997A1 (en) 2014-10-02
JP5877902B2 (ja) 2016-03-08
US10441602B2 (en) 2019-10-15
US9040101B2 (en) 2015-05-26
JP2014528925A (ja) 2014-10-30
US11213543B2 (en) 2022-01-04
JP2018065812A (ja) 2018-04-26
WO2013032744A3 (en) 2013-06-20
EP2797606A4 (de) 2015-09-30
US9463169B2 (en) 2016-10-11
CA2878005C (en) 2020-03-10
JP2016128471A (ja) 2016-07-14

Similar Documents

Publication Publication Date Title
US11213543B2 (en) Human gastrointestinal microbiome modulating composition and methods of use
ES2356536B1 (es) Una composición de uso como prebiótico que contiene un extracto de granada y un alimento que incluye dicha composición.
JP7473516B2 (ja) 腸の健康を促す組成物
US20090214511A1 (en) Digestible compositions of inulin for managing blood glucose levels
JP2006508057A (ja) 非グルコース性炭水化物またはペクチンおよび可溶性線維を含む栄養組成物
EP3976051A1 (de) Zusammensetzungen mit 2 -fucosyllactose und gos
WO2015200842A1 (en) Composition comprising metformin and a microbiome modulator
US20070167395A1 (en) Compositions and methods for treating diabetes
US20140314942A1 (en) Method of transforming a meal
JPWO2005082390A1 (ja) 脂肪蓄積抑制剤
Daley The gastrointestinal system
KR20200130030A (ko) 당뇨병 환자와 잠재환자의 혈당조절효과가 있는 요구르트 조성물 제조방법
RU2781248C1 (ru) Специализированный пищевой продукт для диетического лечебного и диетического профилактического питания и способ его применения
EP3235510A1 (de) Nährstoffzusammensetzungen zur verwaltung des glucosestoffwechsels
US20170239306A1 (en) Soybean extracts and combinations thereof with polyethoxylated castor oil and other adjuvants for controling blood sugar levels and for hepatoprotection
JP2011241216A (ja) モズク由来のフコイダンを含む食品
EP3082466B1 (de) Verwendung von thylakoiden zur reduzierung des drangs nach wohlschmeckenden nahrungsmitteln
US20230030835A1 (en) Polyphenol compositions and uses thereof
Frawley The Gastrointestinal System
JP2014529596A (ja) 食事を変換する方法
Salden et al. Effect of hesperidin 2S supplementation on systemic and intestinal metabolic parameters in subjects at risk for metabolic syndrome: a randomized controlled trial
US20170035791A1 (en) Combination of beta-glucosylceramide and polyethoxylated castor oil and other adjuvants for controling blood sugar levels, immunoprotection and hepatoprotection
TW200533300A (en) Composition for inhibting dietary lipid absorption

Legal Events

Date Code Title Description
PUAI Public reference made under article 153(3) epc to a published international application that has entered the european phase

Free format text: ORIGINAL CODE: 0009012

17P Request for examination filed

Effective date: 20140319

AK Designated contracting states

Kind code of ref document: A2

Designated state(s): AL AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HR HU IE IS IT LI LT LU LV MC MK MT NL NO PL PT RO RS SE SI SK SM TR

DAX Request for extension of the european patent (deleted)
A4 Supplementary search report drawn up and despatched

Effective date: 20150831

RIC1 Information provided on ipc code assigned before grant

Ipc: A61P 1/00 20060101ALI20150825BHEP

Ipc: A61K 31/353 20060101ALI20150825BHEP

Ipc: A61K 31/716 20060101ALI20150825BHEP

Ipc: A61K 31/702 20060101ALI20150825BHEP

Ipc: A23L 1/308 20060101ALI20150825BHEP

Ipc: A61K 31/733 20060101AFI20150825BHEP

Ipc: A61P 3/00 20060101ALI20150825BHEP

17Q First examination report despatched

Effective date: 20180321

STAA Information on the status of an ep patent application or granted ep patent

Free format text: STATUS: THE APPLICATION IS DEEMED TO BE WITHDRAWN

18D Application deemed to be withdrawn

Effective date: 20180801